… immunological issues owing to rapid blood clearance of PEGylated nanoparticles (…
PEGylated biopharmaceuticals: current experience and considerations for nonclinical development…

… This review describes the current development status of intravitreally administered drugs for
… the eye, and discusses key preclinical considerations for the evaluation of ocular biologics. …

… Early in preclinical development, the pharmacokinetics of … One example is the PEGylated,
Fc-free antitumor necrosis … the behavior of the biopharmaceutical and the possible influence of …

… PEGylated biopharmaceuticals. The following commercial … Nonclinical data suggest that the
anticancer activity of … the drug product, taking into consideration intended usage and route of …

… It has been experienced that biopharmaceutical manufacturing … , PEGylation (pegylation)
or molecular biology techniques are used to enhance the potential of biobetters. In PEGylation, …

… issues due to its favorable properties. This review presents recent progress in the development
… to be safe for patients who had previously experienced allergic reactions to E. coli or …

… : “Shifting paradigms: biopharmaceuticals versus low molecular … as it is at present unknown
how the preclinical observations of … One example is the withdrawal of a PEGylated peptide …

… of developing nanopharmaceuticals, the issue of preclinical in … PEGylation of ADA solved
these issues. Davis et al. … hemophilia A in patients who experience repeated bleeding events […

… biopharmaceuticals while reducing toxicity and improving stability [10,11]. Despite the great
importance of PEGylation… haemophilia A developed anti-PEG antibodies and experienced …

… consideration as a new product. This chapter reviews historical and current regulatory
guidelines specific to PEGylated … The nonclinical safety evaluation of biopharmaceuticals applies …